Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

Bringing state-of-the-art healthcare to Florida heart patients
Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.
SCAI leaders 'on a mission' to improve cath lab protection from radiation, orthopedic injury
SCAI President James Hermiller, Jr., MD, explains the need for more innovative radiation protection systems in the cath lab.
How AI and CCTA help heart teams plan ahead before PCI
Evan Shlofmitz, DO, director of intravascular imaging at St. Francis Hospital, explains how advanced artificial intelligence technology is used to assess a patient's CT scan before they undergo PCI.
An updated look at the use of cerebral embolic protection devices during TAVR
Cardiologist Aakriti Gupta, MD, MSc, spoke to Cardiovascular Business about the latest data and trends associated with using cerebral embolic protection devices during TAVR to lower the risk of stroke.
THT 2025: Late-breaking clinical trials announced for CRF’s heart failure conference
The annual conference is now in its fourth year. Attendees are encouraged to leave their ties, jackets and skirts at home and embrace a more casual dress code.

Researchers presented their findings at TCT 2021, noting that TAVR and surgery had similar mortality rates after five years.

The analysis, presented at TCT 2021, examined total costs after two years for more than 900 patients who underwent TAVR or SAVR.

The analysis, presented at TCT 2021, included input from 400 patients with high blood pressure.

The findings were presented at TCT 2021 and published in the New England Journal of Medicine.

The three-day event is sponsored by the Cardiovascular Research Foundation.

New two-year findings, presented at TVT 2021, suggest that the Watchman FLX device is a safe alternative to long-term oral anticoagulation therapy.

The findings were presented Friday, Oct. 16, at TCT Connect 2020.

The findings were presented Thursday, Oct. 15, at TCT Connect 2020.